Obracin (Tobramycin)

Tobramycin, the active ingredient in Obracin, is an aminoglycoside antibiotic presented as a sterile injectable solution for intravenous or intramuscular use. It treats serious Gram‑negative bacterial infections, such as those caused by Pseudomonas aeruginosa, in hospitalized adults and children requiring parenteral therapy. The formulation meets EU pharmacopeial standards and is produced under stringent quality controls.

GNH USA supplies Obracin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide.

Obracin (tobramycin) is used to treat infections caused by Gram‑negative bacteria in several clinical settings.

- Hospital‑acquired pneumonia: effective against Pseudomonas and other Gram‑negative pathogens. - Complicated urinary tract infection: eradicates susceptible Gram‑negative organisms. - Intra‑abdominal infection: used in combination therapy for severe intra‑abdominal sepsis. - Cystic fibrosis lung infection (inhalation): reduces Pseudomonas colonisation in the airways.

Adverse reactions to tobramycin may vary in frequency and severity.

Common Side Effects: - Nephrotoxicity: elevated serum creatinine or reduced urine output. - Ototoxicity: transient tinnitus or hearing loss. - Vestibular dysfunction: dizziness or balance disturbances. - Injection site pain: local discomfort or erythema.

Serious or Rare Side Effects: - Permanent hearing loss: irreversible auditory damage. - Severe renal failure: acute kidney injury requiring dialysis. - Neuromuscular blockade: respiratory muscle weakness. - Allergic reactions: rash, urticaria, or anaphylaxis.

When using Obracin, clinicians should observe specific safety measures. - Renal function monitoring: assess serum creatinine before and during therapy. - Auditory testing: perform baseline and periodic hearing assessments. - Dose adjustment: modify dose in patients with impaired renal clearance. - Concomitant nephrotoxins: avoid or closely monitor use with other kidney‑toxic drugs. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at room temperature: keep in original container, protect from moisture and light.

Tobramycin may interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Loop diuretics (e.g., furosemide): increased risk of nephrotoxicity. - Other aminoglycosides: additive ototoxic and nephrotoxic effects. - Neuromuscular blocking agents (e.g., vecuronium): enhanced muscle weakness.

Moderate Interactions (Monitor Closely): - Vancomycin: potential synergistic nephrotoxicity. - NSAIDs: may reduce renal clearance, increasing toxicity risk. - ACE inhibitors or ARBs: may impair renal function, requiring dose adjustment.